Who are Inactivated SARS-CoV-2 Vaccine (Vero cell）'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): COVAX only (1st and 2nd dose), CCP, Sinopharm BIBP, CoronaVac/CoronaVac, CoronaVac Vaccine, Inactivated SARS-CoV-2 vaccine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/inactivated-sars-cov-2-vaccine-vero-cell.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Inactivated SARS-CoV-2 Vaccine (Vero cell） — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Inactivated SARS-CoV-2 Vaccine (Vero cell） (Inactivated SARS-CoV-2 Vaccine (Vero cell）) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: inactivated viral vaccine. Area: Immunology / Infectious Disease.

marketed inactivated viral vaccine SARS-CoV-2 spike protein and other viral antigens Immunology / Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

Inactivated SARS-CoV-2 Vaccine (Vero cell） (Inactivated SARS-CoV-2 Vaccine (Vero cell）) — Sinovac Research and Development Co., Ltd.. This inactivated vaccine stimulates the immune system to produce antibodies and cellular immunity against SARS-CoV-2 by presenting whole inactivated viral particles.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Inactivated SARS-CoV-2 Vaccine (Vero cell） TARGET	Inactivated SARS-CoV-2 Vaccine (Vero cell）	Sinovac Research and Development Co., Ltd.	marketed	inactivated viral vaccine	SARS-CoV-2 spike protein and other viral antigens
COVAX only (1st and 2nd dose)	COVAX only (1st and 2nd dose)	China National Biotec Group Company Limited	marketed	Inactivated viral vaccine	SARS-CoV-2 spike protein and other viral antigens
CCP	CCP	Metro Infectious Disease Consultants	marketed	Convalescent plasma	SARS-CoV-2 spike protein and other viral antigens
Sinopharm BIBP	Sinopharm BIBP	Vaxxinity, Inc.	phase 3	Inactivated viral vaccine	SARS-CoV-2 spike protein and other viral antigens
CoronaVac/CoronaVac	CoronaVac/CoronaVac	Institut Pasteur de Tunis	phase 3	Inactivated viral vaccine	SARS-CoV-2 spike protein and other viral antigens
CoronaVac Vaccine	CoronaVac Vaccine	Clover Biopharmaceuticals AUS Pty	phase 3	Inactivated viral vaccine	SARS-CoV-2 spike protein and other viral antigens
Inactivated SARS-CoV-2 vaccine	Inactivated SARS-CoV-2 vaccine	Jiangsu Province Centers for Disease Control and Prevention	phase 3	Inactivated viral vaccine	SARS-CoV-2 spike protein and other viral antigens

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (inactivated viral vaccine class)

Sinovac Biotech Co., Ltd · 5 drugs in this class
Sinovac Research and Development Co., Ltd. · 2 drugs in this class
Sanofi Pasteur, a Sanofi Company · 2 drugs in this class
Federal University of Espirito Santo · 1 drug in this class
International Vaccine Institute · 1 drug in this class
MacroGenics · 1 drug in this class
Shandong Province Centers for Disease Control and Prevention · 1 drug in this class
Beijing Chaoyang District Centre for Disease Control and Prevention · 1 drug in this class
Zhejiang Provincial Center for Disease Control and Prevention · 1 drug in this class
Centers for Disease Control and Prevention · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Inactivated SARS-CoV-2 Vaccine (Vero cell） — Competitive Intelligence Brief. https://druglandscape.com/ci/inactivated-sars-cov-2-vaccine-vero-cell. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab